chronic hepatitis B
Conditions
Interventions
HBeAg positive :no
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 60 years old; 2. liver function compensated (no history of ascites, hepatic encephalopathy or upper gastrointestinal bleeding); 3. pregnancy test of childbearing age women is negative; 4. HBeAg positive CHB before NAs treatment: NAs treatment= 12 months, HBV DNA was undetected=12 months (Roche diagnostic reagent kit was selected for screening, the lower limit of detection of HBV DNA was 20 IU/ml), HBeAg seroconversion had occurred =6 months, HBsAg <1500IU/ml, and ALT=1.5ULN; 5. HBeAg-negative CHB before initional of NAs treatment: NAs treatment=12 months, HBV DNA was undetected=12(Roche diagnostic reagent kit was selected for screening, the lower limit of detection of HBV DNA was 20 IU/m), HBsAg<1500 IU/ml and ALT=1.5 ULN; 6. fundus oculi examination was normal; 7. previously used interferon-alpha (Interferon-alpha, IFN-alpha) or PegIFN-alpha, the use of the last dose of interferon should be within a distance of 6 months or more; 8. obtain the informed consent of the subjects.
Exclusion criteria
Exclusion criteria: 1. The telbivudine was included in the NAs antiviral regimen at enrollment; 2. Interleukin and its components are allergic; 3. neutrophils 50ng/mL; or a history of suspected malignancy or malignancy over the past 5 years; 8. mental illness, uncontrollable epilepsy; 9. subjects receiving corticosteroid, immunosuppressive, and chemotherapeutic drugs within 6 months prior to enrollment; 10. Women with pregnancy, lactation and pregnancy planning during the study; 11. ultrasound or CT imaging examination indicated cirrhosis, or suggested any one of the following: LSM=12.0 kPa, or aspartate aminotransferase and platelet ratio index (APRI )> 2 points, or liver biopsy pathology in the most recent 1 year is indicative of cirrhosis; 12. receiving trial medication within the last 3 months; 13. serum total bilirubin> 2.0 ×ULN; 14. poor compliance; 15. researcher believe there are other conditions that may not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV RNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic histopathology; | — |
Countries
China
Contacts
Public ContactSujun Zheng
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed